Neurotoxicity of ecstasy (MDMA): An overview

Current Pharmaceutical Biotechnology

Volumn 11, Issue 5, 2010, Pages 460-469

  Sarkar, Sumit ^a   Schmued, Larry ^a  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

Author keywords

Fluoro jade B; Hyperthermia; MDMA; Neurodegeneration; Neurotoxicity; Serotonin

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; AMINE OXIDASE (FLAVIN CONTAINING); DOPAMINE; DRUG METABOLITE; GLUTAMIC ACID; NITRIC OXIDE; SEROTONIN; SEROTONIN 2A RECEPTOR;

ARTICLE; DRUG ABUSE; DRUG EFFECT; DRUG MECHANISM; DRUG METABOLISM; EXCITOTOXICITY; HEART ARRHYTHMIA; HUMAN; HYPERTENSION; HYPERTHERMIA; INSULA; LIVER DISEASE; MOOD DISORDER; NERVE CELL DEGENERATION; NEUROTOXICITY; NONHUMAN; PARIETAL LOBE; SEIZURE; SEROTONIN SYNDROME; THALAMUS;

ANIMALS; BRAIN; HALLUCINOGENS; HUMANS; MICE; MODELS, NEUROLOGICAL; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NERVOUS SYSTEM DISEASES; RATS;

ANIMALIA; MUS; RATTUS; TENIA;

EID: 77956576593     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920110791591490     Document Type: Article

References (106)

1. Freudenmann, R. W.; Oxler, F.; Bernschneider-Reif, S. The originof MDMA (ecstasy) revisited: the true story reconstructed from theoriginal documents. Addiction, 2006, 101(9), 1241-5
2. Pentney, A. R. An exploration of the history and controversiessurrounding MDMA and MDA. J. Psychoactive Drugs, 2001,33(3), 213-21
3. Greer, G.; Strassman, R. J. Information on Ecstasy. Am. J. Psy-chiatry, 1985, 142(11), 1391
4. Grinspoon, L.; Bakalar, J. B. Can drugs be used to enhance thepsychotherapeutic process? Am. J. Psychother., 1986, 40(3), 393-404
5. DEA, Orange Book. US Department of Justice, Drug EnforcementAdministration (DEA) 2008
6. Parrott, A. C. Is ecstasy MDMA? A review of the proportion ofecstasy tablets containing MDMA, their dosage levels, and thechanging perceptions of purity. Psychopharmacology (Berl)., 2004,173(3-4), 234-41
7. Crean, R. D.; Davis, S. A.; Von Huben, S. N.; Lay, C. C.; Katner, S. N.; Taffe, M. A. Effects of (+/-)3,4-methylenedioxy-methamphetamine(+/-)3,4-methylenedioxyamphetamine and meth-amphetamine on temperature and activity in rhesus macaques. Neu-roscience, 2006, 142(2), 515-25
8. Hall, A. P.; Henry, J. A. Acute toxic effects of 'Ecstasy' (MDMA)and related compounds: overview of pathophysiology and clinicalmanagement. Br. J. Anaesth., 2006, 96(6), 678-85
9. Sprague, J. E.; Preston, A. S.; Leifheit, M.; Woodside, B. Hippo-campal serotonergic damage induced by MDMA (ecstasy): effectson spatial learning. Physiol. Behav., 2003, 79(2), 281-7
10. Yamamoto, B. K.; Spanos, L. J. The acute effects of methylenedi-oxymethamphetamine on dopamine release in the awake-behavingrat. Eur. J. Pharmacol., 1988, 148(2), 195-203
11. Johnson, M. P.; Hoffman, A. J.; Nichols, D. E. Effects of the enan-tiomers of MDA, MDMA and related analogues on [3H]serotoninand [3H]dopamine release from superfused rat brain slices. Eur. J.Pharmacol., 1986, 132(2-3), 269-76
12. Schmidt, C. J. Neurotoxicity of the psychedelic amphetamine,methylenedioxymethamphetamine. J. Pharmacol. Exp. Ther., 1987,240(1), 1-7
13. Schmidt, C. J.; Levin, J. A.; Lovenberg, W. In vitro and in vivoneurochemical effects of methylenedioxymethamphetamine onstriatal monoaminergic systems in the rat brain. Biochem. Pharma-col., 1987, 36(5), 747-55
14. de la Torre, R.; Farre, M.; Roset, P. N.; Pizarro, N.; Abanades, S.; Segura, M.; Segura, J.; Cami, J. Human pharmacology of MDMA:pharmacokinetics, metabolism, and disposition. Ther. Drug Monit.,2004, 26(2), 137-44
15. Berger, U. V.; Gu, X. F.; Azmitia, E. C. The substituted ampheta-mines 3,4-methylenedioxymethamphetamine, methamphetamine,p-chloroamphetamine and fenfluramine induce 5-hydroxy-tryptamine release via a common mechanism blocked by fluoxetineand cocaine. Eur. J. Pharmacol., 1992, 215(2-3), 153-60
16. Crespi, D.; Mennini, T.; Gobbi, M. Carrier-dependent and Ca(2+)-dependent 5-HT and dopamine release induced by (+)-amphetamine, 3,4-methylendioxymethamphetamine, p-chloroam-phetamine and (+)-fenfluramine. Br. J. Pharmacol., 1997, 121(8),1735-43
17. Rothman, R. B.; Baumann, M. H.; Dersch, C. M.; Romero, D. V.; Rice, K. C.; Carroll, F. I.; Partilla, J. S. Amphetamine-type centralnervous system stimulants release norepinephrine more potentlythan they release dopamine and serotonin. Synapse, 2001, 39(1),32-41
18. Han, D. D.; Gu, H. H. Comparison of the monoamine transportersfrom human and mouse in their sensitivities to psychostimulantdrugs. BMC Pharmacol., 2006, 6, 6
19. Rothman, R. B.; Baumann, M. H. Therapeutic potential of mono-amine transporter substrates. Curr. Top. Med. Chem., 2006, 6(17),1845-59
20. Rudnick, G.; Clark, J. From synapse to vesicle: the reuptake andstorage of biogenic amine neurotransmitters. Biochim. Biophys.Acta., 1993, 1144(3), 249-63
21. Goodwin, J. S.; Larson, G. A.; Swant, J.; Sen, N.; Javitch, J. A.; Zahniser, N. R.; De Felice, L. J.; Khoshbouei, H. Amphetamineand methamphetamine differentially affect dopamine transportersin vitro and in vivo. J. Biol. Chem., 2009, 284(5), 2978-89
22. Pifl, C.; Wolf, A.; Rebernik, P.; Reither, H.; Berger, M. L. Zincregulates the dopamine transporter in a membrane potential andchloride dependent manner. Neuropharmacology, 2009, 56(2), 531-40
23. Baumann, M. H.; Rothman, R. B. Neural and cardiac toxicitiesassociated with 3,4-methylenedioxymethamphetamine (MDMA).Int. Rev. Neurobiol., 2009, 88, 257-96
24. Baumann, M. H.; Clark, R. D.; Budzynski, A. G.; Partilla, J. S.; Blough, B. E.; Rothman, R. B. N-substituted piperazines abused byhumans mimic the molecular mechanism of 3,4-methylene-dioxymethamphetamine (MDMA, or 'Ecstasy'). Neuropsycho-pharmacology, 2005, 30(3), 550-60
25. Gudelsky, G. A.; Nash, J. F. Carrier-mediated release of serotoninby 3,4-methylenedioxymethamphetamine: implications for sero-tonin-dopamine interactions. J. Neurochem., 1996, 66(1), 243-9
26. Kankaanpaa, A.; Meririnne, E.; Lillsunde, P.; Seppala, T. The acuteeffects of amphetamine derivatives on extracellular serotonin anddopamine levels in rat nucleus accumbens. Pharmacol. Biochem. Behav., 1998, 59(4), 1003-9
27. Yamamoto, B. K.; Nash, J. F.; Gudelsky, G. A. Modulation ofmethylenedioxymethamphetamine-induced striatal dopamine re-lease by the interaction between serotonin and gamma-aminobutyric acid in the substantia nigra. J. Pharmacol. Exp. Ther.,1995, 273(3), 1063-70
28. Cole, J. C.; Sumnall, H. R. The pre-clinical behavioural pharma-cology of 3,4-methylenedioxymethamphetamine (MDMA). Neuro-sci. Biobehav. Rev., 2003, 27(3), 199-217
29. Green, A. R.; Mechan, A. O.; Elliott, J. M.; O'Shea, E.; Colado, M.I. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy). Pharma-col. Rev., 2003, 55(3), 463-508
30. Gold, L. H.; Koob, G. F.; Geyer, M. A. Stimulant and hallucino-genic behavioral profiles of 3,4-methylenedioxymethamphetamineand N-ethyl-3,4-methylenedioxyamphetamine in rats. J. Pharma-col. Exp. Ther., 1988, 247(2), 547-55
31. Slikker, W. Jr.; Holson, R. R.; Ali, S. F.; Kolta, M. G.; Paule, M.G.; Scallet, A. C.; McMillan, D. E.; Bailey, J. R.; Hong, J. S.; Scalzo, F. M. Behavioral and neurochemical effects of orally ad-ministered MDMA in the rodent and nonhuman primate. Neuro-toxicology, 1989, 10(3), 529-42
32. Spanos, L. J.; Yamamoto, B. K. Acute and subchronic effects ofmethylenedioxymethamphetamine [(+/-)MDMA] on locomotionand serotonin syndrome behavior in the rat. Pharmacol. Biochem.Behav., 1989, 32(4), 835-40
33. Lyles, J.; Cadet, J. L. Methylenedioxymethamphetamine (MDMA,Ecstasy) neurotoxicity: cellular and molecular mechanisms. BrainRes. Brain Res. Rev., 2003, 42(2), 155-68
34. Sprague, J. E.; Everman, S. L.; Nichols, D. E. An integrated hy-pothesis for the serotonergic axonal loss induced by 3,4-methylenedioxymethamphetamine. Neurotoxicology, 1998, 19(3),427-41
35. Battaglia, G.; Brooks, B. P.; Kulsakdinun, C.; De Souza, E. B.Pharmacologic profile of MDMA (3,4-methylenedioxy-methamphetamine) at various brain recognition sites. Eur. J.Pharmacol., 1988, 149(1-2), 159-63
36. Commins, D. L.; Vosmer, G.; Virus, R. M.; Woolverton, W. L.; Schuster, C. R.; Seiden, L. S. Biochemical and histological evi-dence that methylenedioxymethylamphetamine (MDMA) is toxicto neurons in the rat brain. J. Pharmacol. Exp. Ther., 1987, 241(1),338-45
37. Stone, D. M.; Merchant, K. M.; Hanson, G. R.; Gibb, J. W. Imme-diate and long-term effects of 3,4-methylenedioxy-metham-phetamine on serotonin pathways in brain of rat. Neuropharmacol-ogy, 1987, 26(12), 1677-83
38. O'Hearn, E.; Battaglia, G.; De Souza, E. B.; Kuhar, M. J.; Molliver, M. E. Methylenedioxyamphetamine (MDA) and methylenedi-oxymethamphetamine (MDMA) cause selective ablation of sero-tonergic axon terminals in forebrain: immunocytochemical evi-dence for neurotoxicity. J. Neurosci., 1988, 8(8), 2788-803
39. Battaglia, G.; Yeh, S. Y.; De Souza, E. B. MDMA-induced neuro-toxicity: parameters of degeneration and recovery of brain sero-tonin neurons. Pharmacol. Biochem. Behav., 1988, 29(2), 269-74
40. Scanzello, C. R.; Hatzidimitriou, G.; Martello, A. L.; Katz, J. L.; Ricaurte, G. A. Serotonergic recovery after (+/-)3,4-(methyl-enedioxy) methamphetamine injury: observations in rats. J. Phar-macol. Exp. Ther., 1993, 264(3), 1484-91
41. Benmansour, S.; Cecchi, M.; Morilak, D. A.; Gerhardt, G. A.; Javors, M. A.; Gould, G. G.; Frazer, A. Effects of chronic antide-pressant treatments on serotonin transporter function, density, andmRNA level. J. Neurosci., 1999, 19(23), 10494-501
42. Frazer, A.; Benmansour, S. Delayed pharmacological effects ofantidepressants. Mol Psychiatry, 2002, 7 (Suppl 1), S23-8
43. Charlier, C.; Broly, F.; Lhermitte, M.; Pinto, E.; Ansseau, M.; Plomteux, G. Polymorphisms in the CYP 2D6 gene: associationwith plasma concentrations of fluoxetine and paroxetine. Ther.Drug Monit., 2003, 25(6), 738-42
44. Malpass, A.; White, J. M.; Irvine, R. J.; Somogyi, A. A.; Bochner, F. Acute toxicity of 3,4-methylenedioxymethamphetamine(MDMA) in Sprague-Dawley and Dark Agouti rats. Pharmacol.Biochem. Behav., 1999, 64(1), 29-34
45. Maurer, H. H.; Bickeboeller-Friedrich, J.; Kraemer, T.; Peters, F.T. Toxicokinetics and analytical toxicology of amphetamine-derived designer drugs ('Ecstasy'). Toxicol Lett., 2000, 112-113,133-42
46. Escobedo, I.; O'Shea, E.; Orio, L.; Sanchez, V.; Segura, M.; de la Torre, R.; Farre, M.; Green, A. R.; Colado, M. I. A comparativestudy on the acute and long-term effects of MDMA and 3,4-dihydroxymethamphetamine (HHMA) on brain monoamine levelsafter i.p. or striatal administration in mice. Br. J. Pharmacol., 2005,144(2), 231-41
47. Forsling, M. L.; Fallon, J. K.; Shah, D.; Tilbrook, G. S.; Cowan, D.A.; Kicman, A. T.; Hutt, A. J. The effect of 3,4-methylenedioxy-methamphetamine (MDMA, 'ecstasy') and its metabolites on neu-rohypophysial hormone release from the isolated rat hypothalamus.Br. J. Pharmacol., 2002, 135(3), 649-56
48. Baumgarten, H. G.; Lachenmayer, L. Serotonin neurotoxins-pastand present. Neurotox. Res., 2004, 6(7-8), 589-614
49. Monks, T. J.; Jones, D. C.; Bai, F.; Lau, S. S. The role of metabo-lism in 3,4-(+)-methylenedioxyamphetamine and 3,4-(+)-methylenedioxymethamphetamine (ecstasy) toxicity. Ther. DrugMonit., 2004, 26(2), 132-6
50. Winneke, G.; Lilienthal, H. Extrapolation from animals to humans:scientific and regulatory aspects. Toxicol.Lett., 1992, 64-65 Spec No, 239-46.
51. Tancer, M.; Johanson, C. E. Reinforcing, subjective, and physio-logical effects of MDMA in humans: a comparison with d-amphetamine and mCPP. Drug Alcohol. Depend, 2003, 72(1), 33-44
52. Wakonigg, G.; Sturm, K.; Saria, A.; Zernig, G. Methylenedi-oxymethamphetamine (MDMA, 'ecstasy') serves as a robust posi-tive reinforcer in a rat runway procedure. Pharmacology, 2003,69(4), 180-2
53. Finnegan, K. T.; Ricaurte, G. A.; Ritchie, L. D.; Irwin, I.; Peroutka, S. J.; Langston, J. W. Orally administered MDMA causes a long-term depletion of serotonin in rat brain. Brain Res., 1988, 447(1),141-4
54. Fantegrossi, W. E.; Ciullo, J. R.; Wakabayashi, K. T.; De La Garza, R.; Traynor, J. R.; Woods, J. H. A comparison of the physio-logical, behavioral, neurochemical and microglial effects of meth-amphetamine and 3,4-methylenedioxymethamphetamine in themouse. Neuroscience, 2008, 151(2), 533-43
55. Miller, D. B.; O'Callaghan, J. P. The role of temperature, stress,and other factors in the neurotoxicity of the substituted ampheta-mines 3,4-methylenedioxymethamphetamine and fenfluramine. Mol. Neurobiol., 1995, 11(1-3), 177-92
56. Orio, L.; O'Shea, E.; Sanchez, V.; Pradillo, J. M.; Escobedo, I.; Camarero, J.; Moro, M. A.; Green, A. R.; Colado, M. I. 3,4-Methylenedioxymethamphetamine increases interleukin-1beta lev-els and activates microglia in rat brain: studies on the relationshipwith acute hyperthermia and 5-HT depletion. J. Neurochem., 2004,89(6), 1445-53
57. Molliver, M. E.; Berger, U. V.; Mamounas, L. A.; Molliver, D. C.; O'Hearn, E.; Wilson, M. A. Neurotoxicity of MDMA and relatedcompounds: anatomic studies. Ann. N.Y. Acad. Sci., 1990, 600, 649-61; discussion 661-4.
58. Ricaurte, G. A.; Yuan, J.; McCann, U.D. (+/-)3,4-Methylene-dioxymethamphetamine ('Ecstasy')-induced serotonin neurotoxic-ity: studies in animals. Neuropsychobiology, 2000, 42(1), 5-10
59. Jensen, K. F.; Olin, J.; HaykalCoates, N.; O'Callaghan, J.; Miller, D. B.; de Olmos, J. S. Mapping toxicant-induced nervous systemdamage with a cupric silver stain: a quantitative analysis of neuraldegeneration induced by 3,4-methylenedioxymethamphetamine.NIDA. Res. Monogr., 1993, 136, 133-49; discussion 150-4
60. de Olmos, J. S.; Beltramino, C. A.; de Olmos de Lorenzo, S. Use ofan amino-cupric-silver technique for the detection of early andsemiacute neuronal degeneration caused by neurotoxicants, hy-poxia, and physical trauma. Neurotoxicol. Teratol., 1994, 16(6),545-61
61. Schmued, L. C. Demonstration and localization of neuronal degen-eration in the rat forebrain following a single exposure to MDMA. Brain. Res., 2003, 974(1-2), 127-33
62. Ricaurte, G.; Bryan, G.; Strauss, L.; Seiden, L.; Schuster, C. Hallu-cinogenic amphetamine selectively destroys brain serotonin nerveterminals. Science, 1985, 229(4717), 986-8
63. Schmued, L. C.; Hopkins, K. J. Fluoro-Jade B: a high affinity fluo-rescent marker for the localization of neuronal degeneration. BrainRes., 2000, 874(2), 123-30
64. Bowyer, J. F.; Thomas, M.; Schmued, L. C.; Ali, S. F. Brain re-gion-specific neurodegenerative profiles showing the relative im-portance of amphetamine dose, hyperthermia, seizures, and theblood-brain barrier. Ann. N.Y. Acad. Sci., 2008, 1139, 127-39
65. Colado, M. I.; O'Shea, E.; Granados, R.; Misra, A.; Murray, T. K.; Green, A. R. A study of the neurotoxic effect of MDMA ('ecstasy')on 5-HT neurones in the brains of mothers and neonates followingadministration of the drug during pregnancy. Br. J. Pharmacol.,1997, 121(4), 827-33
66. Campbell, N. G.; Koprich, J. B.; Kanaan, N. M.; Lipton, J. W. MDMA administration to pregnant Sprague-Dawley rats results inits passage to the fetal compartment. Neurotoxicol. Teratol., 2006,28(4), 459-65
67. Broening, H. W.; Bowyer, J. F.; Slikker, W. Jr. Age-dependentsensitivity of rats to the long-term effects of the serotonergic neuro-toxicant (+/-)-3,4-methylenedioxymethamphetamine (MDMA) cor-relates with the magnitude of the MDMA-induced thermal re-sponse. J. Pharmacol. Exp. Ther., 1995, 275(1), 325-33
68. Kelly, P. A.; Ritchie, I. M.; Quate, L.; McBean, D. E.; Olverman, H. J. Functional consequences of perinatal exposure to 3,4-methylenedioxymethamphetamine in rat brain. Br. J. Pharmacol.,2002, 137(7), 963-70
69. Koprich, J. B.; Campbell, N. G.; Lipton, J. W. Neonatal 3,4-methylenedioxymethamphetamine (ecstasy) alters dopamine andserotonin neurochemistry and increases brain-derived neurotrophicfactor in the forebrain and brainstem of the rat. Brain Res. Dev.Brain Res., 2003, 147(1-2), 177-82
70. Meyer, J. S.; Ali, S. F. Serotonergic neurotoxicity of MDMA (ec-stasy) in the developing rat brain. Ann. N.Y. Acad. Sci., 2002, 965,373-80
71. Meyer, J. S.; Grande, M.; Johnson, K.; Ali, S. F. Neurotoxic effectsof MDMA (ecstasy) administration to neonatal rats. Int. J. Dev.Neurosci., 2004, 22(5-6), 261-71
72. Broening, H. W.; Morford, L. L.; Inman-Wood, S. L.; Fukumura, M.; Vorhees, C. V. 3,4-methylenedioxymethamphetamine (ec-stasy)-induced learning and memory impairments depend on theage of exposure during early development. J. Neurosci., 2001,21(9), 3228-35
73. Sanchez, V.; O'Shea, E.; Saadat, K. S.; Elliott, J. M.; Colado, M. I.; Green, A. R. Effect of repeated ('binge') dosing of MDMA to ratshoused at normal and high temperature on neurotoxic damage tocerebral 5-HT and dopamine neurones. J. Psychopharmacol., 2004,18(3), 412-6
74. O'Shea, E.; Escobedo, I.; Orio, L.; Sanchez, V.; Navarro, M.; Green, A. R.; Colado, M. I. Elevation of ambient room temperaturehas differential effects on MDMA-induced 5-HT and dopamine re-lease in striatum and nucleus accumbens of rats. Neuropsycho-pharmacology, 2005, 30(7), 1312-23
75. O'Shea, E.; Granados, R.; Esteban, B.; Colado, M. I.; Green, A. R. The relationship between the degree of neurodegeneration of ratbrain 5-HT nerve terminals and the dose and frequency of admini-stration of MDMA ('ecstasy'). Neuropharmacology, 1998, 37(7),919-26
76. Freedman, R. R.; Johanson, C. E.; Tancer, M. E. Thermoregulatoryeffects of 3,4-methylenedioxymethamphetamine (MDMA) in hu-mans. Psychopharmacology (Berl), 2005, 183(2), 248-56
77. Von Huben, S. N.; Lay, C. C.; Crean, R. D.; Davis, S. A.; Katner, S. N.; Taffe, M. A. Impact of ambient temperature on hyperthermiainduced by (+/-)3,4-methylenedioxymethamphetamine in rhesusmacaques. Neuropsychopharmacology, 2007, 32(3), 673-81
78. Colado, M. I.; O'Shea, E.; Esteban, B.; Granados, R.; Green, A. R. In vivo evidence against clomethiazole being neuroprotectiveagainst MDMA ('ecstasy')-induced degeneration of rat brain 5-HTnerve terminals by a free radical scavenging mechanism. Neuro-pharmacology, 1999, 38(2), 307-14
79. Shankaran, M.; Yamamoto, B. K.; Gudelsky, G. A. Involvement ofthe serotonin transporter in the formation of hydroxyl radicals in-duced by 3,4-methylenedioxymethamphetamine. Eur. J. Pharma-col., 1999, 385(2-3), 103-10
80. Colado, M. I.; Murray, T. K.; Green, A. R. 5-HT loss in rat brainfollowing 3,4-methylenedioxymethamphetamine (MDMA), p-chloroamphetamine and fenfluramine administration and effects ofchlormethiazole and dizocilpine. Br. J. Pharmacol., 1993, 108(3),583-9
81. Breier, J. M.; Bankson, M. G.; Yamamoto, B. K. L-tyrosine con-tributes to (+)-3,4-methylenedioxymethamphetamine-induced sero-tonin depletions. J. Neurosci., 2006, 26(1), 290-9
82. Johnson, M.; Elayan, I.; Hanson, G. R.; Foltz, R. L.; Gibb, J. W.; Lim, H. K. Effects of 3,4-dihydroxymethamphetamine and 2,4,5-trihydroxymethamphetamine, two metabolites of 3,4-methyl-enedioxymethamphetamine, on central serotonergic and dopa-minergic systems. J. Pharmacol. Exp. Ther., 1992, 261(2), 447-53
83. O'Shea, E.; Orio, L.; Escobedo, I.; Sanchez, V.; Camarero, J.; Green, A. R.; Colado, M. I. MDMA-induced neurotoxicity: long-term effects on 5-HT biosynthesis and the influence of ambienttemperature. Br. J. Pharmacol., 2006, 148(6), 778-85
84. Schmidt, C. J.; Kehne, J. H., Neurotoxicity of MDMA: neuro-chemical effects. Ann. N.Y. Acad. Sci., 1990, 600, 665-80; discus-sion 680-1.
85. Aguirre, N.; Ballaz, S.; Lasheras, B.; Del Rio, J. MDMA ('Ecstasy')enhances 5-HT1A receptor density and 8-OH-DPAT-induced hy-pothermia: blockade by drugs preventing 5-hydroxytryptamine de-pletion. Eur. J. Pharmacol., 1998, 346(2-3), 181-8
86. Malberg, J. E.; Sabol, K. E.; Seiden, L. S. Co-administration ofMDMA with drugs that protect against MDMA neurotoxicity pro-duces different effects on body temperature in the rat. J. Pharma-col. Exp. Ther., 1996, 278(1), 258-67
87. Sanchez, V.; Camarero, J.; Esteban, B.; Peter, M. J.; Green, A. R.; Colado, M. I. The mechanisms involved in the long-lasting neuro-protective effect of fluoxetine against MDMA ('ecstasy')-induceddegeneration of 5-HT nerve endings in rat brain. Br. J. Pharmacol.,2001, 134(1), 46-57
88. Capela, J. P.; Carmo, H.; Remiao, F.; Bastos, M. L.; Meisel, A.; Carvalho, F. Molecular and cellular mechanisms of ecstasy-induced neurotoxicity: an overview. Mol. Neurobiol., 2009, 39(3),210-71
89. Renoir, T.; Paizanis, E.; Yacoubi, M. E.; Saurini, F.; Hanoun, N.; Melfort, M.; Lesch, K. P.; Hamon, M.; Lanfumey, L. Differentiallong-term effects of MDMA on the serotoninergic system and hip-pocampal cell proliferation in 5-HTT knock-out vs. wild-type mice.Int. J. Neuropsychopharmacol., 2008, 11(8), 1149-62
90. White, S. R.; Duffy, P.; Kalivas, P. W. Methylenedioxymetham-phetamine depresses glutamate-evoked neuronal firing and in-creases extracellular levels of dopamine and serotonin in the nu-cleus accumbens in vivo. Neuroscience, 1994, 62(1), 41-50
91. Farfel, G. M.; Vosmer, G. L.; Seiden, L. S. The N-methyl-D-aspartate antagonist MK-801 protects against serotonin depletionsinduced by methamphetamine, 3,4-methylenedioxy-methamp-hetamine and p-chloroamphetamine. Brain Res., 1992, 595(1), 121-7
92. Farfel, G. M.; Seiden, L. S. Role of hypothermia in the mechanismof protection against serotonergic toxicity. I. Experiments using3,4-methylenedioxymethamphetamine, dizocilpine, CGS 19755and NBQX. J. Pharmacol. Exp. Ther., 1995, 272(2), 860-7
93. Colado, M. I.; Granados, R.; O'Shea, E.; Esteban, B.; Green, A. R.Role of hyperthermia in the protective action of clomethiazoleagainst MDMA ('ecstasy')-induced neurodegeneration, comparisonwith the novel NMDA channel blocker AR-R15896AR. Br. J.Pharmacol., 1998, 124(3), 479-84
94. Zheng, Y.; Laverty, R. Role of brain nitric oxide in (+/-)3,4-methylenedioxymethamphetamine (MDMA)-induced neurotoxicityin rats. Brain Res., 1998, 795(1-2), 257-63
95. Darvesh, A. S.; Gudelsky, G. A. Evidence for a role of energydysregulation in the MDMA-induced depletion of brain 5-HT. Brain Res., 2005, 1056(2), 168-75
96. Erives, G. V.; Lau, S. S.; Monks, T. J. Accumulation of neurotoxicthioether metabolites of 3,4-(+/-)-methylenedioxymetham-pheta-mine in rat brain. J. Pharmacol. Exp. Ther., 2008, 324(1), 284-91
97. Jones, D. C.; Duvauchelle, C.; Ikegami, A.; Olsen, C. M.; Lau, S.S.; de la Torre, R.; Monks, T. J. Serotonergic neurotoxic metabo-lites of ecstasy identified in rat brain. J. Pharmacol. Exp. Ther.,2005, 313(1), 422-31
98. Yeh, S. Y.; Hsu, F. L. The neurochemical and stimulatory effectsof putative metabolites of 3,4-methylenedioxyamphetamine and3,4-methylenedioxymethamphetamine in rats. Pharmacol. Bio-chem. Behav., 1991, 39(3), 787-90
99. Bai, F.; Lau, S. S.; Monks, T. J. Glutathione and N-acetylcysteineconjugates of alpha-methyldopamine produce serotonergic neuro-toxicity: possible role in methylenedioxyamphetamine-mediatedneurotoxicity. Chem. Res. Toxicol., 1999, 12(12), 1150-7
100. Easton, N.; Fry, J.; O'Shea, E.; Watkins, A.; Kingston, S.; Marsden, C. A. Synthesis, in vitro formation, and behavioural effects of glu-tathione regioisomers of alpha-methyldopamine with relevance toMDA and MDMA (ecstasy). Brain Res., 2003, 987(2), 144-54
101. Miller, R. T.; Lau, S. S.; Monks, T. J. Effects of intracerebroven-tricular administration of 5-(glutathion-S-yl)-alpha-methyldo-pamine on brain dopamine, serotonin, and norepinephrine concen-trations in male Sprague-Dawley rats. Chem. Res. Toxicol., 1996,9(2), 457-65
102. Capela, J. P.; Macedo, C.; Branco, P. S.; Ferreira, L. M.; Lobo, A.M.; Fernandes, E.; Remiao, F.; Bastos, M. L.; Dirnagl, U.; Meisel, A.; Carvalho, F. Neurotoxicity mechanisms of thioether ecstasymetabolites. Neuroscience, 2007, 146(4), 1743-57
103. Capela, J. P.; Meisel, A.; Abreu, A. R.; Branco, P. S.; Ferreira, L.M.; Lobo, A. M.; Remiao, F.; Bastos, M. L.; Carvalho, F. Neuro-toxicity of Ecstasy metabolites in rat cortical neurons, and influ-ence of hyperthermia. J. Pharmacol. Exp. Ther., 2006, 316(1), 53-61
104. Stanimirovic, D. B.; Wong, J.; Ball, R.; Durkin, J. P. Free radical-induced endothelial membrane dysfunction at the site of blood-brain barrier: relationship between lipid peroxidation, Na,K-ATPase activity, and 51Cr release. Neurochem. Res., 1995, 20(12),1417-27
105. Quinton, M. S.; Yamamoto, B. K. Causes and consequences ofmethamphetamine and MDMA toxicity. AAPS J., 2006, 8(2),E337-47
106. Paxinos, G. A. W. C. The Rat Brain in Stereotaxic Coordinates. 6 th ed., Academic Press: New York, 2007.